Quarterly report pursuant to Section 13 or 15(d)

EQUITY TRANSACTIONS (Tables)

v3.22.2
EQUITY TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2022
Equity [Abstract]  
SCHEDULE OF COMMON AND PREFERRED STOCK OUTSTANDING

 

    June 30, 2022     December 31, 2021  
Common Stock     257,282       166,394  
Series A Preferred Stock     494,579,119       501,887,534  
SCHEDULE OF ASSUMPTIONS USED TO CALCULATE FAIR VALUE OF STOCK OPTIONS

Inputs used in the valuation models are as follows:

 

2021 Grants
Option value   $ 54.00     to   $ 56.00  
Risk Free Rate     0.90 %   to     1.37 %
Expected Dividend- yield     -     to     -  
Expected Volatility     173.99 %   to     176.04 %
Expected term (years)     5     to     7  
SUMMARY OF STOCK OPTION ACTIVITY

The following is a summary of stock option activity for the six months ended June 30, 2021 and 2022:

 

    Shares    

Weighted

Average

Exercise

Price

    Weighted
Average Remaining
Term (Years)
 
Outstanding at December 31, 2020     410     $ 1,390.00       6.72  
Granted     54,750       70.00       9.75  
Expired/Cancelled     (25 )     216.00        
Outstanding at June 30, 2021     55,135     $ 80.00       9.73  
                         
Exercisable at June 30, 2021     5,718     $ 160.00       9.52  
                         
Outstanding at December 31, 2021     29,635     $ 86.48       9.20  
Granted     -       -       -  
Outstanding at June 30, 2022     29,635     $ 86.48       8.71  
                       
Exercisable at June 30, 2022     19,364     $ 95.22       8.69  
SUMMARY OF STOCK OPTION ACTIVITY NON-VESTED

The following is a summary of the Company’s non-vested shares for the six months ended June 30, 2022:

 

    Shares    

Weighted

Average Grant

Date Fair Value

 
Non-vested at December 31, 2020     -     $ -  
Granted     54,750       60.00  
Vested     (5,333 )     50.00  
Non-vested at June 30, 2021     49,417     $ 60.00  
                 
Non-vested at December 31, 2021     14,250     $ 60.00  
Vested     (3,979 )     54.43  
Non-vested at June 30, 2022     10,271     $ 55.54  
SCHEDULE OF ANTI-DILUTIVE SECURITIES OF BASIC AND DILUTED NET LOSS PER SHARE

The Company excluded the following securities from the calculation of basic and diluted net loss per share as the effect would have been antidilutive:

 

    2022     2021  
    For the Six Months Ended June 30,  
    2022     2021  
Options to purchase common stock (in the money)     -      

4,977

 
Warrants to purchase common stock (in the money)    

384,694

      386,908  
Series A Preferred Stock convertible to common stock     494,579       520,306  
Total     879,273       912,191